

June 14, 2024

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Atsushi Udoh, Representative Director, CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

**Notice Regarding Launch of
3 Ingredients / 8 Products of Generic Drugs for KYOSOMIRAI PHARMA**

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 3 ingredients / 8 products of generic drugs today on June 14, 2024 as below.

New products list

Classes	Product Name	Original Brand Name
Therapeutic agent for allergic disease	EPINASTINE HYDROCHLORIDE TABLETS 10mg /20mg “DAITO”	Alesion Tablets 10 / 20
Therapeutic agent for allergic disease	OLOPATADINE HYDROCHLORIDE TABLETS 2.5mg/5mg “DAITO”	ALLELOCK Tablets 2.5/5
	OLOPATADINE HYDROCHLORIDE OD TABLETS 2.5mg/5mg “DAITO”	ALLELOCK OD Tablets 2.5/5
Parkinson's disease drug Parkinsonism in dementia with Lewy bodies (levodopa activator)	Zonisamide OD Tablets 25mg TRE “DAITO”	TRERIEF OD Tablets 25mg
Parkinson's disease drug (levodopa activator)	Zonisamide OD Tablets 50mg TRE “DAITO”	TRERIEF OD Tablets 50mg